Hengrui Pharmaceuticals Co. Ltd. is out-licensing to GSK plc its potential best-in-class phase I phosphodiesterase 3 and 4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease along ...

GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese ...

China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 other programmes to GlaxoSmithKline Intellectual Property (GSK) for $500 ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and inflammation.

GSK has signed a $500 million upfront licensing deal with Jiangsu Hengrui to secure global rights to its COPD drug HRS‑9821 ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to ...

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several ...

Hengrui Pharma enters agreement and with GSK to develop up to 12 innovative medicines across respiratory, immunology & inflammation & oncology: Jiangsu, China Tuesday, July 29, 20 ...

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPDAdditional 11 programmes to be developed by Hengrui Pharma and optioned by GSK ...

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPDAdditional 11 programmes to be developed by Hengrui Pharma and optioned by GSK ...